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Abstract 7 
Microneedles (MNs) are designed to specifically target the outermost, skin barrier layer, the stratum 8 
corneum, creating transient pathways for minimally invasive transcutaneous delivery. It is reported 9 
that MNs can facilitate delivery without stimulating the pain receptors or damaging blood vessels 10 
that lie beneath, thus being perceived as painless and associated with reduced bleeding. This 11 
immunocompetence of the skin, coupled with its ease of access, makes this organ an attractive 12 
vaccination site. The purpose of this review was to collate primary scientific literature pertaining to 13 
MN-mediated in vivo vaccination programmes. A total of 62 original research articles are presented, 14 
compiling vaccination strategies in 6 different models (mouse, rat, guinea pig, rabbit, pig, macaque 15 
and human). Vaccines tested span a wide range of viral, bacterial and protozoan pathogens and 16 
includes 7 of the 13 vaccine-preventable diseases, as defined by the WHO. This review highlights the 17 
paucity of available clinical trial data. MN-delivered vaccines have demonstrated safety and 18 
immunogenicity in pre-clinical models and boast desirable attributes such as painless administration, 19 
thermostability, dose-sparing capacity and the potential for self-administration. These advantages 20 
should contribute to enhanced global vaccine access. 21 
1. Introduction 22 
1.1 Vaccine delivery 23 
Vaccines are conventionally administered using a hypodermic needle [1]. This form of administration 24 
provides a rapid and direct method of vaccine delivery. Despite familiarity, widespread use and 25 
proven efficacy, the hypodermic needle is associated with accidental needle stick injury, spread of 26 
blood-borne infections [2-4], as well as phobias, pain and significant anxiety [5-8]. In addition, these 27 
needles are not easily self-administered, unless the individual has received specialised training on  28 
injection technique and needle disposal [9]. Oral vaccination is an attractive alternative [10] and a 29 
limited number of oral vaccines have been approved for human use [11-15]. However, this mode of 30 
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immunisation can be less effective, as vaccine antigens undergo digestion in the gastrointestinal 31 
tract prior to induction of an adequate immune response [10] and research on their use has been 32 
limited almost exclusively to protection against mucosally transmitted pathogens, with some notable 33 
recent exceptions [15]. The transdermal route, based on diffusion, has also been investigated. 34 
However this route limits delivery only to lipophilic, low molecular weight potent products [16] and 35 
would prevent a vaccine from crossing the skin due to the presence of the relatively impermeable, 36 
outer stratum corneum (SC) layer. Intradermal vaccination is not a novel concept. In 1910, French 37 
physician Charles Mantoux published his clinical research on the intradermal injection of tuberculin 38 
as a diagnostic test for tuberculosis disease [17]. This diagnostic technique formed the basis for 39 
intradermal vaccination, a technique still in use for vaccines such as rabies [18] and BCG [19]. 40 
However, intradermal delivery is technically challenging, requiring significant operator training [20] 41 
and has been associated with adverse events such as pain, inflammatory changes [21] and the 42 
development of abscesses [22].Taking into account the limitations of parenteral, oral and traditional 43 
transdermal and intradermal vaccination, the concept of the microneedle (MN) emerged as a 44 
solution to these issues. MNs can be 1µm in diameter and range from 50µm to 1000µm in length, 45 
while mini-needles range from 1000µm to 1500µm [23]. They  are designed to specifically target the 46 
outermost, rate limiting, skin barrier layer, the SC, creating transient pathways for minimally invasive 47 
transcutaneous delivery [24]. There are four different types of MNs: solid, coated, hollow and 48 
dissolving. It is reported that MNs can facilitate delivery through SC interruption without stimulating 49 
the pain receptors and blood vessels that lie beneath, thus being perceived as painless and 50 
associated with a reduction in bleeding [1, 25, 26]. Other advantages of microneedle-mediated 51 
delivery include avoidance of first pass metabolism; potential for highly targeted administration to 52 
individual cells [26, 27]; improved patient compliance [28]; dose sparing [29, 30]; thermostability of 53 
certain platforms [31-33] and potential for self-administration.   54 
1.2 The skin: an immune organ and vaccine target 55 
Skin is the largest immune organ in the human body [34], composed of two primary layers, the 56 
epidermis and dermis [35]. These layers provide a protective interface between internal organs and 57 
the external environment, encountering a host of toxins, pathogenic organisms and physical stresses 58 
[36]. The skin functions as more than just a physical barrier. It is capable of mounting a potent 59 
immune response due to the residence of specialised antigen presenting cells. Langerhans cells are 60 
abundant in the epidermis, comprising 2% to 4% of epithelial cells [36], while more classical 61 
dendritic  cells are found in the dermis [36-40]. Other immune-competent accessory cells residing in 62 
the skin include keratinocytes, epidermal cells which play a role in initiating cell-mediated immune 63 
responses through the release of cytokines and the expression of cellular adhesion molecules to 64 
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facilitate movement and coordination with other immune cells; T lymphocytes; melanocytes, 65 
epidermal pigment cells which produce a number of cytokines that mediate inflammation and mast 66 
cells, leukocytes which modulate host innate immune response through the release of granular and 67 
secreted mediators and recruit multiple inflammatory cells through the production of chemotactic 68 
factors [36, 41-43]. The resident professional  APC are adept at antigen capture, and upon 69 
appropriate activation through intracellular interaction, migrate to proximal lymph nodes to activate 70 
B and T lymphocytes and mediate initiation of an adaptive immune response [37, 44]. This 71 
immunocompetence, coupled with its ease of access, makes the skin an attractive vaccination 72 
target. 73 
2. Literature review 74 
The purpose of this review is to collate literature detailing the success of MN-mediated in vivo 75 
vaccination programmes. Keywords including ‘microneedle’, ‘solid microneedle’, ‘coated 76 
microneedle’, ‘hollow microneedle’ ‘dissolvable microneedle’, ‘dissolving microneedle’, were 77 
combined with ‘vaccine’, ‘vaccination’ and ‘immunisation’. Using Google as a search engine, these 78 
keywords were combined in various permutations and combinations to search PubMed. This yielded 79 
a total of 748 results. Following removal of duplications, 180 results remained. The title and abstract 80 
of each result were examined and included or excluded in the final review based on the criteria 81 
outlined in Table 1. A total of 62 results were included in the final review [29, 45-105]    . 82 
Table 1: Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
Original research articles Review articles 
MN-mediated vaccine delivery MN-mediated non-vaccine delivery 
Published in English language MN fabrication studies 
in vivo MN administration MN stability studies  
Article available in full  
 83 
2.1 Solid MNs 84 
The simplest forms of MNs are solid devices. Solid MNs create transient micropores in the SC, 85 
thereby increasing permeability of the barrier layer. Vaccine applied onto the treated surface 86 
diffuses into the skin (from a loaded patch or semi-solid formulation) through the pores created by 87 
MN pre-treatment. The applied vaccine can exert a local effect in the skin and a systemic effect 88 
following uptake [1]. Solid MNs have been used to deliver vaccines for diphtheria [45, 46, 48], 89 
influenza [46], hepatitis B [47, 49, 50] and malaria [51, 52] in mice. Microenhancer array devices 90 
were developed to cause mild abrasion of the SC. These devices scrape the skin with blunt-tipped 91 
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microneedles and have been used to increase the delivery of an anthrax vaccine in mice and rabbits 92 
[53], a Japanese encephalitis vaccine in cynomolgus monkeys [56] and a rabies vaccine in humans 93 
[57, 58]. While these devices were shown to be effective, intradermal injection of the vaccine in 94 
each of these studies was significantly more effective, potentially due to inefficient delivery into the 95 
skin from the formulation. In spite of immunogenicity, the popularity of solid MNs has reduced in 96 
recent years, potentially due to the requirement for a multi-step administration process, the lack of 97 
consistency and the increased number of advantages of other MN systems.    98 
2.2 Coated microneedles 99 
Advancement on solid MNs was the development of coated devices. Solid MNs are pre-coated with 100 
a vaccine in a formulation suitable for coating and dissolution [1], thus resulting in a one-step 101 
delivery process. The vaccine coated MNs are inserted into the skin, where dissolution of the vaccine 102 
occurs. Vaccine delivery via coated MNs is limited by the dimensions of the MN shaft and tip [106, 103 
107]. Successful vaccine coated MNs include influenza [54, 55, 59-77], human papillomavirus [78, 104 
79], chikungunya virus [80], West Nile virus [80], rotavirus [81], herpes simplex virus [82] and 105 
hepatitis C [83] in mice, influenza virus [84] and bacillus Calmette-Guérin in guinea pigs [85], 106 
hepatitis B virus in pigs [86], and measles  [87] and polio [88] viruses in rats. This literature search did 107 
not reveal any clinical trials pertaining to vaccine delivery via coated microneedles.   108 
2.3 Hollow microneedles 109 
Hollow MNs provide a pre-defined conduit for vaccine delivery into the skin or other tissue. 110 
Currently there are two hollow MN designs: a single MN or mini-needle, which mimics the 111 
conventional hypodermic needle [108] or an array of multiple MNs [109]. The latter permits 112 
simultaneous application of a vaccine formulation over a wider area of skin, potentially resulting in 113 
higher bioavailability and increasing the likelihood of lymphatic uptake of presented antigens [110]. 114 
Vaccine may be delivered by passive diffusion through the MN. Conversely, a syringe may be 115 
attached to the MN, permitting active vaccine delivery. There are several commercially available 116 
hollow MN systems; Soluvia® is licensed for use [57, 91] and MicronJet® is being clinically tested 117 
[29]. Soluvia® is a pre-fillable microinjection system with a single 1500µm hollow silicon MN, while 118 
MicronJet® is composed of four 600µm hollow silicon MNs arranged on a plastic adaptor for 119 
attachment to a standard syringe barrel [23]. Hollow MNs have been successfully developed to 120 
immunise human subjects with polio [89, 90] or influenza [29, 91, 92] vaccines, to immunise mice 121 
against plague [93] and to administer polio vaccine to rats [94].  122 
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2.4 Dissolving microneedles 123 
The final, most advanced and complex MN is the dissolving MN. Dissolving MNs are polymeric and 124 
encapsulate vaccine within their matrix [1, 111, 112]. Insertion of the MNs into the skin catalyses the 125 
degradation of the polymeric compound, subsequently releasing the vaccine [112]. Unlike the 126 
alternate MN platforms already discussed, dissolving MNs are fully biocompatible and do not 127 
generate biohazardous waste, a distinct advantage [113, 114]. Other advantages include robustness 128 
and scalability [115, 116]. However, unlike hollow MN, a limitation is placed on the amount of 129 
vaccine that can be incorporated into the system [117] and vaccinees may be obliged to wait for 130 
extended periods of time to ensure complete MN degradation [114]. Dissolving MNs have been 131 
developed to incorporate vaccines for influenza virus [95-100], hepatitis B [101, 102], tetanus [97], 132 
diphtheria [97], malaria [97] and HIV [103] in mice and measles [104] and polio [105] in rhesus 133 
macaques, with a long term aim to create a thermostable, self-administration platform. Although an 134 
attractive platform, dissolvable microneedle (DMN) systems for vaccine delivery have required more 135 
time to reach clinical trials compared to hollow or solid microneedles. Hollow and solid MN devices 136 
have  a traditional medical device classification. In contrast, DMN patches will likely be seen, from a 137 
regulatory perspective, as  a combination product of a medicinal product (the vaccine) and a device 138 
(potential backing layers and/or applicators). However, as a new dosage format, the product 139 
specifications, critical quality attributes of each product and regulatory pathway of DMN systems has 140 
not yet been defined. Furthermore, to ensure the quality of vaccine-loaded DMN patches that will 141 
be clinically used, they must be produced in the appropriate environment that complies with, good 142 
manufacturing practice (GMP). These processes, guidelines and regulatory strategies are only 143 
recently being defined [118]. 144 
3. Discussion 145 
The purpose of this review was to collate primary scientific literature pertaining to MN-mediated in 146 
vivo vaccination programmes, according to the inclusion and exclusion criteria outlined in Table 1. A 147 
total of 62 original research articles are presented, compiling vaccination strategies in 6 different 148 
models (mouse [45-52, 54, 55, 59-83, 93, 95-103], rat [87, 88, 94], guinea pig [84, 85], rabbit [53], pig 149 
[86], cynomolgus [56] or rhesus macaque [104, 105]) and in human subjects [29, 57, 58, 89-92]. The 150 
review highlights MN compatibility with live, inactivated, subunit and DNA vaccines. Vaccines tested 151 
span a wide range of viral, bacterial and protozoan pathogens; including influenza [29, 46, 54, 55, 59-152 
77, 84, 91, 92, 95-100], hepatitis B [47, 49, 50, 86, 101, 102], Japanese encephalitis [56], rabies [57, 153 
58], human papillomavirus [78, 79], chikungunya virus [80], West Nile virus [80], rotavirus [81], 154 
herpes simplex [82], hepatitis C [83], measles [87, 104], polio [88-90, 94, 105] and HIV [103], 155 
bacterial illnesses including diphtheria [45, 46, 48, 97], anthrax [53], tuberculosis [85], plague [93] 156 
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and tetanus [97] and protozoan illnesses including malaria [51, 52, 97], as summarised in Table 2. 157 
This list includes 7 of the 13 vaccine-preventable diseases, as defined by the WHO [119]. This review 158 
highlights the paucity of clinical trial data, with only 11.29% of the 62 trials presented conducted in 159 
human subjects. 160 
Table 2: Disease targets for microneedle-mediated vaccine delivery 
Model Virus Bacteria Protozoa 
Mouse Hepatitis B [47, 49, 50, 101, 102] 
Influenza [46, 54, 55, 59-77, 95-100] 
Human papillomavirus [78, 79] 
West Nile virus [80] 
Chikungunya virus [80] 
Rotavirus [81] 
Herpes simplex [82] 
Hepatitis C [83]  
HIV [103] 





Malaria [51, 52, 97] 
Rat Measles [87] 
Polio [88, 94] 
  
Guinea Pig Influenza [84] Tuberculosis [85]  
Rabbit  Anthrax [120]  
Pig Hepatitis B [86]   




Human Influenza [29, 91, 92] 
Rabies [57, 58] 
Polio [89, 90] 
  
 161 
3.1 Influenza: a popular vaccine target 162 
The influenza virus vaccine is as a popular vaccine target, being the pathogen of interest in 32 of the 163 
62 research articles presented. Influenza is a highly contagious respiratory illness, with influenza A 164 
and B viruses causing annual seasonal epidemics and sporadic pandemics of disease, leading to 165 
hospitalisations and occasionally death [121-125]. In the US, it is estimated that influenza resulted in 166 
greater than half a million hospitalisations, 18,491-95,390 intensive care admissions and 4,915-167 
27,174 deaths per year between 2010 and 2013 [126]. Investment in the development of an 168 
influenza vaccine offers significant commercial and technical gain. Unlike other vaccines, which offer 169 
life-long immunity with a single dose, influenza immunity requires annual re-vaccination as a result 170 
of antigenic variation of the virus [127]. The target end-user of a microneedle patch-based influenza 171 
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vaccine is the adult population and not the paediatric, thus reducing the barrier to clinical use. 172 
Vaccination is effective in preventing infection [128]. Furthermore, unlike many other vaccines, 173 
serological correlates of protection exist and the CHMP criteria are accepted to measure 174 
immunogenicity. However, coverage rates in target populations are far below the WHO-175 
recommended 75% [129-131]. In addition, there are unmet needs associated with current influenza 176 
vaccines [132]. This motivates the development of alternate delivery systems such as MNs that may 177 
offer enhanced vaccine uptake and acceptance [133]. If a MN-based vaccine exhibited enhanced 178 
stability and lower vaccine doses could be used [29, 30], then this could be attractive to vaccine 179 
manufacturers. From a user perspective, the prospect of a painless, potentially self-administered 180 
vaccine may lead to improved vaccination coverage [28]. However all of these features still remain 181 
to be rigorously tested and developed in a clinical context.  182 
3.2 Improving vaccine coverage in developing countries 183 
Even though vaccination programmes are frequently cited as one of the most low-cost, high-impact 184 
public health measures  [134], 1.5 million children die every year as a result of vaccine preventable 185 
illnesses, including some of those presented in this review. Vaccines are temperature sensitive 186 
biological products, requiring refrigeration. In many developing world countries, a cold-chain 187 
infrastructure is almost prohibitively expensive thus preventing adequate vaccine distribution [135, 188 
136]. The thermostability of MN vaccines eliminates cold-chain requirements, thus reducing logistic 189 
costs and potentially improving distribution [31-33]. This thermostability would permit stock-piling in 190 
regular drug distribution networks, combatting the frequently encountered issue of supply shortage. 191 
In addition to being thermolabile, conventional vaccines often require administration by trained 192 
personnel. In LMIC countries, there are shortages of medical personnel at all levels of training [137]: 193 
Africa has 2.3 healthcare workers per 1000 population, compared to 24.8 per 1000 in the Americas 194 
[138]. Therefore the previously discussed potential for self-administration with MN vaccines could 195 
further improve vaccine coverage in these countries, in tandem with other public health efforts. 196 
However, most paediatric vaccines in the Expanded Programme of Immunization are adjuvanted. 197 
Pharmaceutical, immunological, safety and efficacy issues of incorporating licensed adjuvants into 198 
solid dosage formats of microneedles must be addressed before this technology will be licensed and 199 
deployed for these vaccines. Significant research and development effort is being focussed in these 200 
areas to resolve these concerns.  201 
3.3 Translation into clinical use 202 
This review presents a variety of MN vaccines in the pre-clinical development stage, demonstrating 203 
safety and immunogenicity in animal models but also highlights the scarcity of clinical trial data. 204 
There is a progression from evaluation in small animal models such as mice, to higher animal models 205 
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such as rhesus macaques, prior to transition to clinical development and evaluation in human 206 
subjects [139]. While preclinical research answers basic questions, it is not a surrogate for clinical 207 
research. It is hoped that the MN vaccines presented in this review, especially those that have 208 
undergone assessment in non-human primates, will progress through the developmental stages, 209 
ultimately leading to vaccine licensing and introduction into clinical use. An issue that needs to be 210 
assessed is the habituality of hypodermic needle-mediated vaccination. Despite the aforementioned 211 
disadvantages, traditional immunisation has repeatedly demonstrated efficacy and safety. 212 
Familiarity breeds acceptance. Therefore a paradigm shift is required to drive the transition of MN-213 
vaccines into clinical use. Increased end-user acceptability of MN-based vaccines will be required for 214 
widespread adoption. Positive attributes such as pain-free, bloodless administration must be 215 
rigorously tested and defined and acceptance of this technology by the end-user must be assessed, 216 
understood and the technology adapted to incorporate end-users’ needs. MN fabrication 217 
considerations include scalability and dose loading capacity must also be addressed so that the 218 
vaccine manufacturer can assimilate the technology into their fill-finish systems. The majority of MN 219 
research has been conducted at laboratory scale in small quantities and the development of 220 
alternate fabrication approaches has begun to demonstrate scalability  [140, 141]. There is an 221 
inherent dose loading capacity associated with some MN technologies, whereby there is a limit to 222 
the amount of vaccine that can be coated on or incorporated in the MN [1]. The inclusion of 223 
adjuvants may reduce the vaccine dose required to elicit an appropriate immune response [86, 142], 224 
although their inclusion will also necessitate appropriate validation and production in GMP 225 
environments. Finally, there is a need for the development of universal acceptance criteria and Good 226 
Manufacturing Practice specifications, permitting MN characterisation and subsequent 227 
commercialisation [118]. 228 
This review presented the research pertaining to in vivo MN vaccines. Vaccines have been delivered 229 
via solid, coated, hollow and dissolving MNs. The dissolving MN offers a significant advantage over 230 
other MN platforms: the elimination of sharp, biohazardous waste after vaccination. MNs have the 231 
potential to improve vaccine access in developing countries. These vaccines have demonstrated 232 
safety and immunogenicity in pre-clinical models. The paucity of clinical data presented in this 233 
review highlights the need to incentivise vaccine research in human subjects. The technology 234 
possesses desirable attributes for the end-user including painless administration and potential for 235 
self-application, which may increase compliance and subsequent vaccine coverage, as well as 236 
benefits for the manufacturer including thermostability and dose-sparing capacity. All of these 237 
advantages demonstrate the high potential for microneedle technologies to have a positive impact 238 
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